{"filing":{"accession_number":"0001178253-26-000035","cik":"0001178253","ticker":"SCYX","company_name":"SCYNEXIS INC","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-18","primary_document":"scyx-20260918.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1178253/000117825326000035/scyx-20260918.htm"},"events":[{"id":34195,"run_id":31463,"accession_number":"0001178253-26-000035","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Steven K. Burke, M.D., was appointed to the Board of Directors effective September 18, 2026, and to the Nominating and Corporate Governance Committee. Dr. Burke brings 30+ years of biopharmaceutical industry experience with specific expertise in drug development for chronic kidney disease, directly relevant to the company's SCY-770 program for ADPKD.","company_name":"SCYNEXIS INC","ticker":"SCYX","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37864,"accession_number":"0001178253-26-000035","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Steven K. Burke, M.D., as a member of the Board of Directors effective September 18, 2026, and his appointment to the Nominating and Corporate Governance Committee. While the disclosure includes compensatory arrangements (annual retainers, stock options, and RSUs), the principal disclosed action is the appointment of a director with significant industry expertise in drug development for chronic kidney disease, which is material to the company's strategy around its SCY-770 program. The appointment is the primary event; compensation details are secondary disclosures required by Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:06:50.315448+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37865,"accession_number":"0001178253-26-000035","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Steven K. Burke to SCYNEXIS's Board of Directors, effective September 18, 2026. The press release emphasizes his 30+ years of biopharmaceutical industry experience and specific expertise in drug development for chronic kidney disease, directly relevant to the company's SCY-770 program for ADPKD. This is a material governance event affecting board composition and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:06:50.315448+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37864,"accession_number":"0001178253-26-000035","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Steven K. Burke, M.D., as a member of the Board of Directors effective September 18, 2026, and his appointment to the Nominating and Corporate Governance Committee. While the disclosure includes compensatory arrangements (annual retainers, stock options, and RSUs), the principal disclosed action is the appointment of a director with significant industry expertise in drug development for chronic kidney disease, which is material to the company's strategy around its SCY-770 program. The appointment is the primary event; compensation details are secondary disclosures required by Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:06:50.315448+00:00","company_name":"SCYNEXIS INC","ticker":"SCYX","filing_date":"2026-09-22"},{"id":37865,"accession_number":"0001178253-26-000035","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Steven K. Burke to SCYNEXIS's Board of Directors, effective September 18, 2026. The press release emphasizes his 30+ years of biopharmaceutical industry experience and specific expertise in drug development for chronic kidney disease, directly relevant to the company's SCY-770 program for ADPKD. This is a material governance event affecting board composition and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:06:50.315448+00:00","company_name":"SCYNEXIS INC","ticker":"SCYX","filing_date":"2026-09-22"}]}